NSC 281311 | 54241-03-1

• 分子结构分类: 有机化合物 - 核苷、核苷酸和类似物 - 嘌呤核苷
• 英文名称: NSC 281311
• 英文别名: N⁶-[(3,4-dihydroxyphenyl)ethyl]adenosine；N-[(3,4-dimethoxyphenyl)ethyl]adenosine；3,4-di-hydroxyphenylethyladenosine；N⁶-(3,4-dihydroxy-phenethyl)-adenosine；N-[(3,4-dihydroxyphenyl)-ethy]-adenosine；(2r,3r,4s,5r)-2-[6-[2-(3,4-Dihydroxyphenyl)ethylamino]purin-9-yl]-5-(hydroxymethyl)tetrahydrofuran-3,4-diol；(2R,3R,4S,5R)-2-[6-[2-(3,4-dihydroxyphenyl)ethylamino]purin-9-yl]-5-(hydroxymethyl)oxolane-3,4-diol
• CAS: 54241-03-1
• 化学式: C₁₈H₂₁N₅O₆
• 分子量: 403.395
• InChiKey: LJSCNWRFGRIEQT-SCFUHWHPSA-N

物化性质

• 沸点：
  835.1±75.0 °C(Predicted)
• 密度：
  1.74±0.1 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  0.9
• 重原子数：
  29
• 可旋转键数：
  6
• 环数：
  4.0
• sp3杂化的碳原子比例：
  0.39
• 拓扑面积：
  166
• 氢给体数：
  6
• 氢受体数：
  10

反应信息

• 作为产物：
  描述：

  盐酸多巴胺 、 6-氯嘌呤核苷 在 三乙胺 作用下， 以 丙醇 为溶剂， 反应 8.0h， 生成 NSC 281311
  参考文献：
  名称：

  Ｎ６−置換アデノシン誘導体とＮ６−置換アデニン誘導体の鎮静、催眠、抗うつ、抗痙攣、抗てんかん、抗パーキンソン病と認知証予防・治療の用途

  摘要：

  该专利涉及调整止痛药、催眠药、抗痉挛药、抗癫痫药、抗帕金森病和认知症预防药以及健康食品的组合。解决方案特点在于选择自特定化合物组中的N6-取代腺苷诱导体或N6-取代腺嘌呤诱导体。此外，医药组合物特点在于至少包含治疗有效量的上述化合物和药学上可接受的载体。进一步，该化合物特点在于用于调整止痛药、催眠药、抗痉挛药、抗癫痫药、抗帕金森病和认知症预防药以及健康食品。【选择图】无

  公开号：

  JP2015172077A

文献信息

• N6-SUBSTITUTED ADENOSINE DERIVATIVES AND N6-SUBSTITUTED ADENINE DERIVATIVES AND USES THEREOF
  申请人：Shi Jiangong

  公开号：US20130045942A1

  公开（公告）日：2013-02-21

  The present invention provides N 6 -substituted adenosine derivatives and N 6 -substituted adenine derivatives, manufacturing methods thereof, a pharmaceutical composition comprising the said compounds above, and uses of these compounds in manufacturing medicaments and health-care products for treating insomnia, convulsion, epilepsy, and Parkinson's diseases, and preventing and treating dementia.

  本发明提供了N6-取代腺苷衍生物和N6-取代腺嘌呤衍生物，其制备方法，包括上述化合物的药物组合物，以及这些化合物在制造治疗失眠、惊厥、癫痫和帕金森病的药物和保健产品以及预防和治疗痴呆症中的用途。
• Adenosine Analogues as Inhibitors of <i>Trypanosoma </i><i>b</i><i>rucei </i>Phosphoglycerate Kinase:  Elucidation of a Novel Binding Mode for a 2-Amino-N⁶-Substituted Adenosine
  作者：Jerome C. Bressi、Jungwoo Choe、Melinda T. Hough、Frederick S. Buckner、Wesley C. Van Voorhis、Christophe L. M. J. Verlinde、Wim G. J. Hol、Michael H. Gelb

  DOI：10.1021/jm000287a

  日期：2000.11.1

  As part of a project aimed at structure-based design of adenosine analogues as drugs against African trypanosomiasis, N-6-, 2-amino-N-6-, and N-2-substituted adenosine analogues were synthesized and tested to establish structure-activity relationships for inhibiting Trypanosoma brucei glycosomal phosphoglycerate kinase (PGK), glyceraldehyde-3-phosphate dehydrogenase (GAPDH), and glycerol-3-phosphate dehydrogenase (GPDH). Evaluation of X-ray structures of parasite PGK, GAPDH, and GPDH complexed with their adenosyl-bearing substrates led us to generate a series of adenosine analogues which would target all three enzymes simultaneously. There was a modest preference by PGK for NG-substituted analogues bearing the 2-amino group. The best compound in this series, 2-amino-N-6-[2 "-(p-hydroxyphenyl)ethyl]adenosine (46b), displayed a 23-fold improvement over adenosine with an IC50 of 130 muM. 2-[[2 "-(p-Hydroxyphenyl)ethyl]amino]adenosine (46c) was a weak inhibitor of T. brucei PGK with an IC50 of 500 muM. To explore the potential of an additive effect that having the N-6 and N-2 substitutions in one molecule might provide, the best ligands from the two series were incorporated into N-6,N-2-disubstituted adenosine analogues to yield N-6-(2 " -phenylethyl)-2-[(2 " -phenylethyl)amino]adenosine (69) as a 30 muM inhibitor of T. brucei PGK which is 100-fold more potent than the adenosine template. In contrast, these series gave no compounds that inhibited parasitic GAPDH or GPDH more than 10-20% when tested at 1.0 mM. A 3.0 Angstrom X-ray structure of a T, brucei PGK/46b complex revealed a binding mode in which the nucleoside analogue was flipped and the ribosyl moiety adopted a syn conformation as compared with the previously determined binding mode of ADP. Molecular docking experiments using QXP and SAS program suites reproduced this "flipped and rotated" binding mode.
• EP2511283
  申请人：——

  公开号：——

  公开（公告）日：——
• Ｎ６−置換アデノシン誘導体とＮ６−置換アデニン誘導体の鎮静、催眠、抗うつ、抗痙攣、抗てんかん、抗パーキンソン病と認知証予防・治療の用途
  申请人：中国医学科学院葯物研究所

  公开号：JP2015172077A

  公开（公告）日：2015-10-01

  【課題】鎮痛剤、催眠、抗痙攣薬、抗てんかん薬、抗パーキンソン病や認知症予防薬や健康食品の調整を行うこと。【解決手段】特定の化合物のグループから選択されることを特徴とする、Ｎ６−置換アデノシン誘導体またはＮ６−置換アデニン誘導体。 また、治療上有効な量の上記化合物と、薬学的に許容される担体とを少なくとも含有することを特徴とする、医薬組成物。 さらに、鎮痛剤、催眠、抗痙攣薬、抗てんかん薬、抗パーキンソン病や認知症予防薬や健康食品の調整において使用されることを特徴とする、上記化合物。【選択図】なし

  该专利涉及调整止痛药、催眠药、抗痉挛药、抗癫痫药、抗帕金森病和认知症预防药以及健康食品的组合。解决方案特点在于选择自特定化合物组中的N6-取代腺苷诱导体或N6-取代腺嘌呤诱导体。此外，医药组合物特点在于至少包含治疗有效量的上述化合物和药学上可接受的载体。进一步，该化合物特点在于用于调整止痛药、催眠药、抗痉挛药、抗癫痫药、抗帕金森病和认知症预防药以及健康食品。【选择图】无